Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)
106.49
-1.30
(-1.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2026
Add to My Watchlist
Price and Volume
Detailed Quote| Volume | 1,014,918 |
| Open | 108.85 |
| Bid (Size) | 100.00 (200) |
| Ask (Size) | 109.00 (100) |
| Prev. Close | 107.79 |
| Today's Range | 105.71 - 110.00 |
| 52wk Range | 14.51 - 110.17 |
| Shares Outstanding | 101,192,921 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
These stocks are gapping in today's session ↗
April 13, 2026
VR Adviser Adds Over 1 Million Savara Shares ↗
March 15, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
Frequently Asked Questions
Is Spyre Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spyre Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spyre Therapeutics, Inc. - Common Stock trade on?
Spyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spyre Therapeutics, Inc. - Common Stock?
The ticker symbol for Spyre Therapeutics, Inc. - Common Stock is SYRE on the Nasdaq Stock Market
What is the current price of Spyre Therapeutics, Inc. - Common Stock?
The current price of Spyre Therapeutics, Inc. - Common Stock is 106.49
When was Spyre Therapeutics, Inc. - Common Stock last traded?
The last trade of Spyre Therapeutics, Inc. - Common Stock was at 08/21/26 04:00 PM ET
What is the market capitalization of Spyre Therapeutics, Inc. - Common Stock?
The market capitalization of Spyre Therapeutics, Inc. - Common Stock is 10.78B
How many shares of Spyre Therapeutics, Inc. - Common Stock are outstanding?
Spyre Therapeutics, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.